Wednesday, September 7, 2016
Aduro Biotech has announced the opening of a new corporate office and laboratory facility, which will serve as the company’s new global headquarters for its U.S. and European operations.
The IMS Institute for Healthcare Informatics has announced the launch of a new branch focused on supporting improved health outcomes across Asia. Based in Singapore, the team will forge relationships in the public and private sectors and apply analytics-driven approaches, based on Real-World Evidence, for disease modeling and insights—providing regional markets with much-needed tools to make better and more cost-effective healthcare policy decisions.
Medivir has announced that the Board of Directors has tasked the company management to continue the implementation of a separation of the company’s operations into two independent companies, with the intention to obtain a separate listing on First North Premium for the new commercial company based on Medivir’s current pharmaceutical portfolio. The objective of the separation is to visualize the value of both the commercial operations and the pharmaceutical projects that make up the R&D portfolio.
The number of drug candidates in clinical trials from Massachusetts-headquartered companies increased by 14% from 2014, and the total number of drug candidates increased to 1,645, a 10% increase, according to an annual industry report published by MassBio.
Last Monday, Pfizer and Medivation announced their merger, with Pfizer buying Medivation for $14 billion in cash. Pfizer won out over numerous other bidders, including Celgene, Gilead Sciences, Merck and Sanofi.
BioLineRx, a clinical stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, has established a joint venture (JV) with I-Bridge Capital, a Chinese venture capital fund focused on developing innovative therapies in China. The joint venture, named iPharma, will develop innovative clinical and preclinical therapeutic candidates originating primarily in Israel to serve the Chinese and global healthcare markets.
Biomedical Systems, a 40-year-old, family-owned, clinical trial provider to pharmaceutical, medical device, biotech and CROs, has announced a new partnership with digital health company Foundry Health of Chicago. The two companies will collaborate on the development of a proprietary cloud-based data management system that will allow sponsors immediate access to clinical trial data in real time.
Casebia Therapeutics, the joint venture founded by Bayer and CRISPR Therapeutics, started its operations in Cambridge, Massachusetts. In December, 2015 Bayer and CRISPR Therapeutics agreed to create a joint venture to discover, develop and commercialize new breakthrough therapeutics to cure blood disorders, blindness and congenital heart disease. The two parties formally closed the transaction in the first quarter of 2016.